Please use this identifier to cite or link to this item: https://doi.org/10.1111/j.1432-2277.2008.00801.x
DC FieldValue
dc.titleFactors associated with proteinuria in renal transplant recipients treated with sirolimus
dc.contributor.authorLiew, Adrian
dc.contributor.authorChiang, Gilbert SC
dc.contributor.authorVathsala, Anantharaman
dc.date.accessioned2022-07-29T07:05:07Z
dc.date.available2022-07-29T07:05:07Z
dc.date.issued2009-03-01
dc.identifier.citationLiew, Adrian, Chiang, Gilbert SC, Vathsala, Anantharaman (2009-03-01). Factors associated with proteinuria in renal transplant recipients treated with sirolimus. TRANSPLANT INTERNATIONAL 22 (3) : 313-322. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1432-2277.2008.00801.x
dc.identifier.issn0934-0874
dc.identifier.issn1432-2277
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/229443
dc.description.abstractAlthough sirolimus (SRL) use in renal allograft recipients (RTX) is associated with improved renal function, proteinuria develops in a significant proportion. 48 SRL-treated RTX were evaluated for development of proteinuria and stratified by level of proteinuria after SRL therapy. The Proteinuria Group (n = 25, 52.1%) had new-onset proteinuria or >25% increase in proteinuria following SRL conversion; the Nonproteinuria Group had stable proteinuria <0.5 g/day throughout. There was a higher proportion of male RTX and female donors to male recipients in the Proteinuria Group, (24% vs. 10%, P = 0.008). Calcineurin inhibitor- and statin usage were significantly higher in the Nonproteinuria Group (8% vs. 17%, P = 0.046; 28% vs. 83%, P < 0.001 respectively) whereas biopsy-proven acute rejection was higher in the Proteinuria Group (68% vs. 33%, P = 0.037). SDS-PAGE analysis of urine from 23 RTX in the Proteinuria Group demonstrated glomerular proteinuria in 100% and tubular proteinuria in 87%. While male gender and gender mismatch may impact on glomerular proteinuria through inadequate nephron dose and subsequent hyperfiltration, concurrent cyclosporine use may mitigate the development of proteinuria in SRL-treated patients, through afferent arteriolar vasoconstriction. Glomerular injury occurring following acute rejection may further contribute to glomerular proteinuria. Statins, through their anti-inflammatory and anti-fibrotic effects, may protect against development of proteinuria. © 2008 The Authors.
dc.language.isoen
dc.publisherWILEY
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectSurgery
dc.subjectTransplantation
dc.subjectcyclosporine
dc.subjectproteinuria
dc.subjectrenal transplantation
dc.subjectsirolimus
dc.subjectstatins
dc.subjectCHRONIC ALLOGRAFT NEPHROPATHY
dc.subjectENDOTHELIAL GROWTH-FACTOR
dc.subjectCALCINEURIN-INHIBITORS
dc.subjectKIDNEY-TRANSPLANTATION
dc.subjectREDUCTASE INHIBITOR
dc.subjectNEPHROTIC SYNDROME
dc.subjectHEAVY PROTEINURIA
dc.subjectACUTE REJECTION
dc.subjectBLOOD-PRESSURE
dc.subjectRAPAMYCIN
dc.typeArticle
dc.date.updated2022-07-23T13:13:22Z
dc.contributor.departmentMEDICINE
dc.description.doi10.1111/j.1432-2277.2008.00801.x
dc.description.sourcetitleTRANSPLANT INTERNATIONAL
dc.description.volume22
dc.description.issue3
dc.description.page313-322
dc.description.placeUNITED KINGDOM
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Factors associated with proteinuria in renal transplant in Sirolimus treated KTX.pdf211.46 kBAdobe PDF

CLOSED

Published

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.